In this instalment of Health Innovators, EiC Jonah Comstock sits down virtually with Fady Malik, EVP of research and development at Cytokinetics and Steve Heitner, the company’s VP of clinical ...

JMP Securities analyst Jason Butler maintained a Buy rating on Cytokinetics (CYTK – Research Report) today and set a price target of $78.00.

$10,000 of CYTOKINETICS INC. lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "General healthcare representation.

Avior Wealth Management LLC decreased its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 7.0% during the 4th quarter, according to its most recent 13F filing with the ...